Ozempic

Ozempic is semaglutide at doses of 0.5 mg, 1.0 mg, and 2.0 mg injected once weekly. It was FDA-approved in December 2017 for type 2 diabetes, and later picked up an indication for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease.

Ozempic is not FDA-approved for weight management. Wegovy is. They are the same molecule, manufactured by the same company, in different pens at different doses.

Because Ozempic was the first GLP-1 to reach cultural salience for its weight-loss effect (roughly 2020–2022), the brand name became shorthand for the whole category. Most of the "Ozempic for weight loss" prescribing that peaked in 2022–2023 was off-label use — legal, but at the lower diabetes dose, and typically without insurance coverage because the ICD-10 code doesn't match the FDA label.

If your primary goal is weight loss, the honest answer is that Wegovy or Zepbound is almost always the right prescription. The exceptions: patients with type 2 diabetes whose plan covers Ozempic at low copay, or patients on Ozempic who already respond well and whose insurance won't transition them.

The key weight-loss evidence actually comes from the semaglutide diabetes program, not dedicated obesity trials. SUSTAIN-7 showed about 6.4 kg (~6% body weight) reduction on 1.0 mg weekly in type 2 diabetics. The STEP-2 trial — which used the 2.4 mg Wegovy dose in type 2 diabetics — produced about 10% weight loss.

Real-world registry data from primary care off-label prescribing suggests average weight loss of ~10–14% for non-diabetic adults who reach the 2.0 mg maintenance dose and stay on drug for 12+ months. This is a half-step below Wegovy (14.9% in STEP-1) because the dose cap is lower.

For patients comparing Ozempic vs Wegovy, the clinically honest framing: same molecule, Wegovy doses higher, Wegovy is the one you want for weight loss if you can get it covered.

Ozempic titrates 0.25 mg for 4 weeks → 0.5 mg → 1.0 mg → (optional) 2.0 mg. Full escalation to 2.0 mg takes ~16 weeks. It's supplied in multi-dose pens; each pen typically holds a month of drug.

Side effect profile is identical to Wegovy because it's the same molecule: nausea, diarrhea, vomiting, constipation, abdominal pain. GI tolerability is generally better at Ozempic doses than at Wegovy doses because lower doses = less side effect burden.

Class warnings are identical: thyroid C-cell tumor boxed warning, pancreatitis, gallbladder disease, retinopathy complications in diabetic patients, hypoglycemia risk with insulin/sulfonylureas, and the one-week pre-op hold recommendation.

List price: about $999/month.

Commercial insurance for diabetes: typical copays of $25–$100/month with the Ozempic Savings Card. Diabetes coverage is much broader than obesity coverage — PBMs have covered GLP-1s for diabetes for years.

Commercial insurance for off-label weight loss: almost never covered. Most plans run edits that check the diagnosis code; obesity-coded Ozempic claims are denied, after which patients typically either pay cash or transition to Wegovy.

Medicare Part D: covered for type 2 diabetes. Not covered for weight management (same statutory barrier as Wegovy).

Cash-pay: $999/month retail. Novo's direct channel offers Ozempic at $499/month for cash-pay diabetic patients meeting specific criteria — narrower than the Wegovy cash program.

Compounded semaglutide: was widespread during the 2022–2024 shortage; dried up significantly after FDA shortage removal in 2025. Compounded supply that remains is often non-identical "semaglutide sodium" of uncertain quality. If weight loss is the goal and compounding is the cost path, most programs now steer toward brand Zepbound or Wegovy via manufacturer cash programs.

Ozempic remains a good choice when:

• You have type 2 diabetes and weight loss is a secondary goal — Ozempic's glycemic effect and CV outcomes data (SUSTAIN-6) are the reason to pick it.
• You're already on Ozempic for diabetes, tolerating it well, and insurance won't easily transition you to Wegovy.
• Your insurance covers Ozempic but not Wegovy — still rare but does happen with certain Medicare Advantage plans.

If weight loss is your primary goal and diabetes isn't involved, skip to Wegovy, Zepbound, or the Wegovy Pill — all are designed and priced for obesity and easier to get covered for that indication.

For diabetes, Ozempic is prescribed through any PCP or endocrinologist and filled at retail pharmacy.

For off-label weight loss, telehealth programs that prescribe Ozempic for weight loss are less common than they were in 2022, because most programs now steer patients to Wegovy, Zepbound, or compounded alternatives. Ro and a handful of others still prescribe off-label when clinically appropriate.

The typical transition path from Ozempic to Wegovy for weight loss: Ozempic 2.0 mg → Wegovy 1.7 mg for 4 weeks → Wegovy 2.4 mg maintenance. Most prescribers will support this switch when the goal is weight loss and insurance cooperates.